Navigation Links
Estrogen replacement therapy speeds ovarian cancer growth, new study reports
Date:10/20/2010

Aurora, Colo. (Oct. 19, 2010) Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center.

Menopausal estrogen replacement therapy (ERT) also significantly increases the likelihood of the cancer metastasizing to the lymph nodes, according to the study, which will be published in the Nov. 1 issue of Cancer Research. The study was released online Oct. 19, 2010. Cancer Research, published by the American Association for Cancer Research, is the world's largest circulation medical journal devoted specifically to cancer research.

The effect of ERT was shown in mouse models of estrogen receptor positive(ER+) ovarian cancer, which accounts for about 60 percent of all human ovarian cancer cases. Ovarian cancer is one of the deadliest cancers affecting women. This year alone, nearly 22,000 women will be newly diagnosed with ovarian cancer and an estimated 13,850 women will die from the disease, according to the National Cancer Institute.

"We showed that estrogen replacement substantially increases proliferation and risk of distant lymph node metastasis in ER+ tumors," says Monique Spillman, MD, PhD, the study's lead researcher, a gynecologic oncologist at University of Colorado Hospital and assistant professor at of obstetrics and gynecology at the University of Colorado School of Medicine.

For the first time, Spillman and her team measured ovarian cancer growth in the abdomen of mice using novel techniques for visualizing the cancer. In mice with ER+ ovarian cancer cells, which were tagged with a firefly-like fluorescent protein that allowed them to be tracked, the introduction of estrogen therapy made the tumors grow five times faster than in mice that did not receive the ERT. The risk of the cancer moving to the lymph nodes increased to 26 percent in these mice compared with 6 percent in mice that did not receive ERT.

The team also found that the estrogen-regulated genes in ovarian cancer reacted differently than ER+ genes found in breast cancer, helping to explain why current anti-estrogen therapies used with breast cancer, such as Tamoxifen, are largely ineffective against ovarian cancer.

"Breast cancer and ovarian cancer are often linked when talking about hormone replacement therapy, but we found that only 10 percent of the ER+ genes overlapped," Spillman says. "We were able to identify estrogen-regulated genes specific to ER+ ovarian cancer that are not shared with ER+ breast cancers. We believe these genes can be specifically targeted with new anti-estrogen therapies that could more effectively treat ER+ ovarian cancers."

Spillman and her team now will begin to screen current antiestrogen therapies against the newly identified ovarian cancer genes to identify the pathways and compounds that are more likely to effectively treat ER+ ovarian cancer.

This study looked at the effect of estrogen replacement therapy in mice that already possessed ER+ ovarian cancer cells. It did not test whether the estrogen replacement actually could cause the development of these cancer cells. The study also dealt only with estrogen replacement, which is linked to higher risks of ovarian cancer, not combined estrogen/progesterone therapy that is used with women who retain their uteruses.

This research is too early to draw implications for use of estrogen replacement therapy in women, Spillman cautions. "We cannot make clinical recommendations based on what is happening in mice," says Spillman, one of just eight gynecological oncologists in Colorado. "Every woman is different and needs to talk to her doctor about the decision to use hormone replacement therapy."


'/>"/>

Contact: Lynn Clark
lynn.clark@ucdenver.edu
303-724-3160
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Tendon Injuries May Be Linked to Estrogen Levels in Female Athletes
2. Team to study health effects of botanical estrogens
3. Estrogen not associated with lung cancer incidence and mortality among postmenopausal women
4. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
5. Scientists find link between estrogen metabolism pathway and breast cancer risk
6. Researchers find key to getting estrogens benefits without cancer risk
7. Progesterone is effective for hot flash treatment and provides an alternative to estrogen
8. Estrogen-lowering drugs minimize surgery in breast cancer patients
9. Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
10. Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds
11. Typical Male Behavior Comes From Estrogen, Too
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: an enlightening ... God’s Work” is the creation of published author, Jerri Broglin, a survivor of great ... “I believe this a great eye-opener for those searching for answers, as we are ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud to present ... be held at 7:30 pm on May 10th at the University Auditorium. , This ... Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will kick off ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is a place ... rendered in my Art and Music. These are created as Metaphysical Transformations where music, ... of mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , Karen will ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... U.S. consumers can save an average of 70% when buying medication online from ... 97%) are available when purchasing from other countries. The report (chart below) compares ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology: